Prostate-specific membrane antigen vaccines: naked DNA and protein approaches.
Prostate-specific membrane antigen (PSMA) is a relatively omnipresent molecule with a multiplicity of functions and has been shown to be a reasonable target for immunologic approaches such as vaccines or more directed therapy with radioactively labeled monoclonal antibodies against PSMA. Given the abundance of various glycoprotein and carbohydrate antigens expressed on the surface of prostate cancer cells and cell lines, PSMA stands out as another self-antigen that is not only expressed on cancer cells but also on neovasculature. Although vaccines are varied in their design and target goal, recent technology has afforded researchers the opportunity to induce recruitment of multiple effector cell populations, cytokines, and factors that can elicit cellular and humoral responses. This review serves to present unique approaches in vaccine development that can induce immunologic responsiveness to PSMA with potential impact on disease progression.
Slovin
Susan F
SF
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center New York, NY 10021, USA. slovins@mskcc.org
D000818:Animals; D019496:Cancer Vaccines; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000276:immunology*; D011471:Prostatic Neoplasms / Q000276:immunology / Q000628:therapy*; D012093:Replicon / Q000276:immunology; D019444:Vaccines, DNA
D019496:Cancer Vaccines; D019444:Vaccines, DNA; D017430:Prostate-Specific Antigen